購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
NKG-hFcRn Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
NKG-hFcRn Mouse
製品名
NKG-hFcRn Mouse
製品ID
C001706
系統名
NOD.Cg-PrkdcscidIl2rgem1Fcgrtem1(hFCGRT)/Cya
背景情報
NKG
状況
このマウス系統を論文で使用する場合は、「NKG-hFcRn Mouse(カタログ番号C001706)はサイアジェンから購入しました。」と引用してください。
Immunodeficient Mice
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Immunodeficient Mice
基本情報
検証 Data
関連リソース
基本情報
遺伝子別名
FCRN, FcgammaRn, alpha-chain, gc, p64, [g]c, CD132, gamma(c)
染色体
Chr 19, Chr X
MGI ID
さらに
系統詳細
NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, exhibits reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues.
Neonatal Fc receptor (FcRn) is a cell surface receptor protein that binds to the Fc region of IgG antibodies. It is structurally similar to MHC class I molecules and comprises an α-chain and β2-microglobulin (β2M). The α-chain of the FcRn receptor is encoded by the Fcγ receptor and transporter (FCGRT) gene, while β2-microglobulin is encoded by the β-2-microglobulin (B2M) gene. FcRn is expressed widely on epithelial cells, endothelial cells, and hematopoietic cells, and is found in various tissues and organs, including the intestine, placenta, kidney, and liver [1-2].
IgG antibodies are the most abundant immunoglobulins in human serum (about 75%), and play an important role in the immune response by defending against pathogens and toxins. Compared to other immunoglobulins, IgG has a high circulating level, a longer half-life, and the ability to be transferred from mother to offspring. These properties are closely related to its interaction with FcRn. FcRn binds to the Fc region of IgG, preventing IgG molecules from being degraded by lysosomes. This prolongs the in vivo half-life of IgG and is involved in the transport, maintenance, and distribution metabolism of IgG. In addition, the specific transport process of IgG from the mother to the fetus to provide the fetus with short-term passive immunity is also mediated by FcRn [1-2]. In addition to its protective role, IgG autoantibodies are also associated with many pathological conditions. Therefore, novel FcRn blocking therapies are an effective strategy to reduce the circulating levels of pathogenic IgG autoantibodies and to reduce IgG-mediated diseases. In addition, many drugs also utilize FcRn's protective mechanism for IgG by fusing or conjugating with the Fc portion of IgG to prolong its serum half-life and improve its pharmacokinetics. The FCGRT gene encodes the α-chain of the FcRn protein, and its homologous genes are present in most mammals.
The NKG-hFcRn mouse is a humanized model constructed by replacing the exon 2 coding region plus partial intron 2 of the mouse Fcgrt gene in situ with the "Human FCGRT CDS-3'UTR of Mouse Fcgrt-WPRE-BGH pA" cassette. It expresses human FcRn to replace the endogenous mouse FcRn. The homozygous NKG-hFcRn mice are viable and fertile. This model may help evaluate the pharmacokinetics/pharmacodynamics of human immunoglobulin G in transplantation research, human tumor xenografts, and mouse tumor allografts.
参考文献
Challa DK, Velmurugan R, Ober RJ, Sally Ward E. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Curr Top Microbiol Immunol. 2014;382:249-72.
Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. J Allergy Clin Immunol. 2020 Sep;146(3):467-478.
系統作製戦略
The exon 2 coding region plus partial intron 2 of mouse Fcgrt was replaced with "Human FCGRT CDS-3'UTR of Mouse Fcgrt-WPRE-BGH pA" cassette.

Figure 1. Gene editing strategy of NKG-hFcRn Mice.
適用分野
In vivo transport, maintenance, and metabolism studies of IgG;
Development and screening of IgG antibody drug candidates;
Pharmacology, Pharmacodynamics, and Pharmacokinetics of IgG antibody drugs;
Evaluation of Fc-based immunotherapy.
検証 Data
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
